Log in
Enquire now
‌

US Patent 7819796 Embryo modification and implantation

Patent 7819796 was granted and assigned to Kode Biotech on October, 2010 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Current Assignee
Kode Biotech
Kode Biotech
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
7819796
Patent Inventor Names
Stephen M. Henry0
Nicola L. Carter0
Deborah A. Blake0
Date of Patent
October 26, 2010
Patent Application Number
10510377
Date Filed
April 7, 2003
Patent Citations Received
‌
US Patent 11696756 Surgical apparatus with conductor strain relief
0
Patent Primary Examiner
‌
Samuel G. Gilbert
Patent abstract

The present invention relates to constructs and methods used to enhance the attachment and implantation of an embryo. It is shown that modified glycolipids and glycolipid-attachment molecule constructs can be used to modify embryos, or localised to target tissues, to enhance interaction between the embryo and the target tissue, (typically the endometrium). The invention may advantageously be used to enhance implantation of embryos in the uterus, for example, in IVF treatments.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 7819796 Embryo modification and implantation

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.